Kodiak Sciences Inc (KOD)
NASDAQ: KODHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KOD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.35B
- EPS (TTM)
- -$4.08
- Dividend yield
- None
- 52-week range
- 20.38 – 112.79
- Day range
- 96.53 – 100.89
- Volume / Avg
- 692.96K / 1.77M
- Beta
- —
- Shares outstanding
- 65.40M
52-week range
KOD stock today
Shares of Kodiak Sciences (KOD) finished lower on Nov 20 at $97.17, a drop of 0.75% or $0.73 per share, versus the S&P 500's 3.70% decline. Trading was light, with 692.96K shares changing hands, about 39% of the average daily volume. At this level, KOD sits near the top of its 52-week range of $20.38 to $112.79: 13.8% below the high, set on Nov 13, 2026 and 376.8% above the low.
KOD is up 247.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 367.8%. Kodiak Sciences has posted a net loss over the last twelve months (EPS of -$4.08), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Kodiak Sciences
Company profileKodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Victor Perlroth M.D.
- Headquarters
- Palo Alto, CA
- Employees
- 144
- IPO year
- 2018
- Website
- kodiak.com
Financial highlights
Full financialsKodiak Sciences reported a net loss of $230.0 million, compared with a loss of $176.2 million a year earlier. Diluted earnings per share came in at -$4.32.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-229.97M | $-176.21M | $-260.49M | $-333.82M | $-266.99M |
| EPS (diluted) | $-4.32 | $-3.35 | $-4.97 | $-6.39 | $-5.16 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$129.50+33.27%
- Strong buy 1
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-1.05 vs $1.00
- Surprise
- -205.00%
KOD news
All KOD news- Kodiak Q3 Loss Wider Than Expected, Pipeline Development in FocusNasdaqKOD, REGN, ACIU, AMRX
- Kodiak Sciences Inc. Reports Third Quarter 2026 Financial Results and Business HighlightsNasdaq
- Kodiak Sciences GAAP EPS of -$1.05 beats by $0.01Seeking Alpha
- Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial ResultsPR Newswire
- Kodiak Sciences to Present at Three Upcoming Investor ConferencesPR Newswire
- Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?NasdaqKOD, REGN
- KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing NearsNasdaqKOD, REGN, ACIU, PGEN
- Biotech Stocks At 52-Week Highs - KOD +177% On Phase 3 Data; GRAL, IOVA, RGENNasdaqIOVA, KOD, RGEN
Kodiak Sciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IBRXImmunityBio Inc. | 6.02 | -8.37% | $6.40B | vs KOD |
| IMVTImmunovant Inc. | 31.77 | -2.31% | $6.57B | vs KOD |
| SRRKScholar Rock Holding Corporation | 48.13 | -4.45% | $5.87B | vs KOD |
| TWSTTwist Bioscience Corporation | 103.32 | -7.44% | $7.04B | vs KOD |
| CGONCG Oncology Inc. | 79.47 | -2.97% | $7.10B | vs KOD |
| ADPTAdaptive Biotechnologies Corporation | 27.93 | -0.43% | $4.52B | vs KOD |
| PCVXVaxcyte Inc. | 55.39 | -5.09% | $8.77B | vs KOD |
| CRSPCRISPR Therapeutics AG | 39.10 | +0.44% | $3.79B | vs KOD |
Indexes, lists and sector
Kodiak Sciences stock FAQ
What is Kodiak Sciences's stock price today?
KOD last traded at $97.17 as of Nov 20, 4:00 PM EST, down 0.75% on the day. Prices are delayed at least 15 minutes.
Who is Kodiak Sciences's CEO?
Dr. Victor Perlroth M.D. is the chief executive officer of Kodiak Sciences Inc, which has about 144 employees.
What is the KOD 52-week high?
The 52-week high for KOD is $112.79 and the 52-week low is $20.38. The stock is currently 13.8% below its high.